Rationally designed less toxic SPD-304 analogs and preliminary evaluation of their TNF inhibitory effects.

SPD-304 was discovered as a promising tumor necrosis factor alpha (TNF) antagonist that promotes dissociation of TNF trimers and therefore blocks the interaction of TNF and its receptor. However, SPD-304 contains a potentially toxic 3-alkylindole moiety, which can be bioactivated to a reactive electrophilic intermediate. A series of SPD-304 analogs was synthesized with the aim to diminish its toxicophore groups while maintaining the binding affinity for TNF. Incorporation of electron-withdrawing substituents at the indole moiety, in conjunction with elimination of the 6'-methyl group of the 4-chromone moiety, led to a significantly less toxic and equally potent TNF inhibitor.

Discovery of Small-Molecule Inhibitors of Receptor Activator of Nuclear Factor-κB Ligand with a Superior Therapeutic Index.

Receptor activator of nuclear factor-κB ligand (RANKL) constitutes the master mediator of osteoclastogenesis, while its pharmaceutical inhibition by a monoclonal antibody has been approved for the treatment of postmenopausal osteoporosis. To date, the pursuit of pharmacologically more favorable approaches using low-molecular-weight inhibitors has been hampered by low specificity and high toxicity issues. This study aimed to discover small-molecule inhibitors targeting RANKL trimer formation. Through a systematic screening of 39 analogues of SPD-304, a dual inhibitor of tumor necrosis factor (TNF) and RANKL trimerization, we identified four compounds (1b, 3b, 4a, and 4c) that selectively inhibited RANKL-induced osteoclastogenesis in a dose-dependent manner, without affecting TNF activity or osteoblast differentiation. Based on structure-activity observations extracted from the most potent and less toxic inhibitors of RANKL-induced osteoclastogenesis, we synthesized a focused set of compounds that revealed three potent inhibitors (19a, 19b, and 20a) with remarkably low cell-toxicity and improved therapeutic indexes as shown by the LC50 to IC50 ratio. These RANKL-selective inhibitors are an excellent starting point for the development of small-molecule therapeutics against osteolytic diseases.

Larvicidal activity of naturally occurring naphthoquinones and derivatives against the West Nile virus vector Culex pipiens.

Concentration-dependent mortality effects were observed for three pure synthetic natural products (alkannin, shikonin, and shikalkin) and three acetylated derivatives of shikonin against Culex pipiens (Culicidae: Diptera) for the first time. The larvicidal properties of all naphthoquinones were evaluated under laboratory conditions against the larvae of the mosquito species C. pipiens biotype molestus, the anthropophilic biotype of the C. pipiens mosquito species. Experimental data of the tested toxicity of quinones revealed generally high efficacy where shikonin (3.9 mg/L) was the most active followed by shikalkin (8.73 mg/L) and alkannin (12.35 mg/L). The insecticidal performance of shikonin-acetylated derivatives was also investigated, aiming at the same time in the establishment of the relationships between the structure and the activity of shikonin-type compounds with larvicidal activity against C. pipiens. Results indicated that naphthoquinones, compared with other natural compounds with larvicidal activity, are very toxic against mosquito larvae and could be a potential source of natural larvicidal substances. Finally, bioassays with shikonin derivatives also revealed that although hydroxylic groups seem to play a secondary role in efficacy, the quinone moiety is essential.

A new efficient route for multigram asymmetric synthesis of alkannin and shikonin.

A short and convergent approach for the synthesis of alkannin, shikonin and shikalkin is presented. A Hauser-type annulation of cyanophthalide 26 with enone 7 affords the complete aromatic system in just one step with concomitant attachment of the entire side chain. Subsequent Corey's oxazaborolidine mediated asymmetric reduction of the above advanced intermediate, leads to the required isomer in high enantiomeric excess. Finally, a selective and high yielding deprotection protocol furnishes the title compounds as pure crystalline precipitates. Thus, a multigram synthesis of shikonin, alkannin and shikalkin is achieved in high yield and enantioselectivity.